Literature DB >> 9824157

Design and properties of a Myc derivative that efficiently homodimerizes.

L Soucek1, M Helmer-Citterich, A Sacco, R Jucker, G Cesareni, S Nasi.   

Abstract

bHLH and bHLHZip are highly conserved structural domains mediating DNA binding and specific protein-protein interactions. They are present in a family of transcription factors, acting as dimers, and their selective dimerization is utilized to switch on and off cell proliferation, differentiation or apoptosis. Myc is a bHLHZip protein involved in growth control and cancer, which operates in a network with the structurally related proteins Max, Mad and Mnt. It does not form homodimers, working as a heterodimer with Max; Max, instead, forms homodimers and heterodimers with Mad and Mnt. Myc/Max dimers activate gene transcription, while Mad/Max and Mnt/Max complexes are Myc/Max antagonists and act as repressors. Modifying the molecular recognition of dimers may provide a tool for interfering with Myc function and, in general, for directing the molecular switches operated via bHLH(Zip) proteins. By molecular modelling and mutagenesis, we analysed the contribution of single amino acids to the molecular recognition of Myc, creating bHLHZip domains with altered dimerization specificity. We report that Myc recognition specificity is encoded in a short region within the leucine zipper; mutation of four amino acids generates a protein, Omomyc, that homodimerizes efficiently and can still heterodimerize with wild type Myc and Max. Omomyc sequestered Myc in complexes with low DNA binding efficiency, preventing binding to Max and inhibiting Myc transcriptional activator function. Consistently with these results, Omomyc produced a proliferation arrest in NIH3T3 cells. These data demonstrate the feasibility of interfering with fundamental biological processes, such as proliferation, by modifying the dimerization selectivity of a bHLHZip protein; this may facilitate the design of peptides of potential pharmacological interest.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9824157     DOI: 10.1038/sj.onc.1202199

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  72 in total

1.  Visualization of Myc/Max/Mad family dimers and the competition for dimerization in living cells.

Authors:  Asya V Grinberg; Chang-Deng Hu; Tom K Kerppola
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

2.  PP2A-mediated regulation of Ras signaling in G2 is essential for stable quiescence and normal G1 length.

Authors:  Nana Naetar; Velmurugan Soundarapandian; Larisa Litovchick; Kelsey L Goguen; Anna A Sablina; Christian Bowman-Colin; Piotr Sicinski; William C Hahn; James A DeCaprio; David M Livingston
Journal:  Mol Cell       Date:  2014-05-22       Impact factor: 17.970

3.  BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal:  Cell       Date:  2011-09-01       Impact factor: 41.582

Review 4.  Therapeutic strategies to inhibit MYC.

Authors:  Michael R McKeown; James E Bradner
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-01       Impact factor: 6.915

5.  OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors.

Authors:  L A Jung; A Gebhardt; W Koelmel; C P Ade; S Walz; J Kuper; B von Eyss; S Letschert; C Redel; L d'Artista; A Biankin; L Zender; M Sauer; E Wolf; G Evan; C Kisker; M Eilers
Journal:  Oncogene       Date:  2016-10-17       Impact factor: 9.867

Review 6.  The ups and downs of Myc biology.

Authors:  Laura Soucek; Gerard I Evan
Journal:  Curr Opin Genet Dev       Date:  2009-12-03       Impact factor: 5.578

7.  Max-E47, a designed minimalist protein that targets the E-box DNA site in vivo and in vitro.

Authors:  Jing Xu; Gang Chen; Antonia T De Jong; S Hesam Shahravan; Jumi A Shin
Journal:  J Am Chem Soc       Date:  2009-06-10       Impact factor: 15.419

Review 8.  MYC protein interactors in gene transcription and cancer.

Authors:  Diana Resetca; Cornelia Redel; Corey Lourenco; Peter Lin; Alannah S MacDonald; Roberto Ciaccio; Tristan M G Kenney; Yong Wei; David W Andrews; Maria Sunnerhagen; Cheryl H Arrowsmith; Brian Raught; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2021-06-29       Impact factor: 60.716

9.  c-Myc and cancer metabolism.

Authors:  Donald M Miller; Shelia D Thomas; Ashraful Islam; David Muench; Kara Sedoris
Journal:  Clin Cancer Res       Date:  2012-10-15       Impact factor: 12.531

10.  Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice.

Authors:  Laura Soucek; Jonathan R Whitfield; Nicole M Sodir; Daniel Massó-Vallés; Erika Serrano; Anthony N Karnezis; Lamorna Brown Swigart; Gerard I Evan
Journal:  Genes Dev       Date:  2013-03-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.